Buy Dsuvia online. DSUVIA contains one 30 mcg sufentanil tablet housed in a disposable single-dose applicator (SDA). The DSUVIA tablet is an immediate release formulation intended for sublingual administration. Each tablet is blue, flat-faced with a diameter of 3 mm. DSUVIA is indicated for use in adults in a certified medically supervised healthcare setting, such as hospitals, surgical centers, and emergency departments, for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.
Significant respiratory depression
Acute or severe bronchial asthma in an unmonitor setting or in the absence of resuscitative equipment
Known or suspect gastrointestinal obstruction, including paralytic ileus
Known hypersensitivity to sufentanil or components of DSUVIA.
- Not for home use or for use in children. Discontinue treatment with DSUVIA before patients leave the certified medically supervised healthcare setting.
- Not for use for more than 72 hours. The use of DSUVIA beyond 72 hours has not been studied.
- Only to be administered by a healthcare provider.
- Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see WARNINGS AND PRECAUTIONS], reserve DSUVIA for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]:
- Have not been tolerated, or are not expected to be tolerated,
- Have not provided adequate analgesia, or are not expected to provide adequate analgesia.
Adverse effects associated with the use of Dsuvia may include, but are not limited to, the following:
Warnings and Precautions
Most Importantly, Accidental Ingestion Or Exposure To Even One Dose Of DSUVIA, Especially In Children, Can Result In Respiratory Depression And Death Due To An Overdose Of Sufentanil.
Certainly, DSUVIA Is For Use In Adult Patients Only In A Certified Medically Supervised Healthcare Setting.
Likewise, Discontinue Use Of DSUVIA Prior To Discharge Or Transfer From The Certified Medically Supervised Healthcare Setting. DSUVIA Is Not For Home Or Pediatric Use.
Therefore, DSUVIA Contains Sufentanil, A Schedule II Controlled Substance. As An Opioid, DSUVIA Exposes Users To The Risks Of Addiction, Abuse, And Misuse.
Profound Sedation, Respiratory Depression, Coma, And Death May Result From The Concomitant Use Of DSUVIA With Benzodiazepines Or Other CNS Depressants (E.G., Non-Benzodiazepine Sedatives/Hypnotics, Anxiolytics, Tranquilizers, Muscle Relaxants, General Anesthetics, Antipsychotics, Other Opioids, Alcohol).
Because Of These Risks, Reserve Concomitant Prescribing Of These Drugs For Use In Patients For Whom Alternative Treatment Options Are Inadequate.